

VOLUME 35,#1

NEWSLETTER

MAY 2024

INSIDE THIS ISSUE:

President's Column	1-2
Meeting Reminders	3
Member Spotlight	4-7
Announcements	8
SCT Sponsors	9
Future SCT Meetings	10
Information About SCT	10



Dixie Ecklund President 2023-2024

Happy Spring!

Greetings to all! Thank you to all of you who have renewed your membership dues for 2024. Membership for 2023 finished strong with 850 members. This was the highest number of members we have seen for the past several years (even pre-pandemic!) We would like to top that number for 2024. If you have not renewed your membership, you are able to do that as part of the registration process for the Annual meeting. Please reach out to the EAI membership coordinator, Kelly Burns at <u>kelly-</u> <u>burns@sctweb.org</u> with any questions.

Plans are coming to fruition for the 45th

SCT President's Column

Annual Meeting of the Society for Clinical Trials in Boston May 19-22. I hope to see you all there! The theme of the meeting this year is "It Takes a Village: Patient-Centered Partnerships in Clinical Trials". This is an important reminder in our day-to-day work in clinical trials that our patient partners are at the very center of the "why". Clinical trials are a very important nexus between sciencedriven decisions and improving health care outcomes. We are honored to have two very distinguished keynote speakers this year. Penney Cowan, founder of the American Chronic Pain Association (ACPA) and a member of the Board of Directors of the World Patients Alliance, will give the Founders Keynote Lecture on Tuesday, May 21, at 8:30 am on "Perspective of Those with Lived Experience: Involving a Patient in Clinical Trials". We will be honoring Curtis Meinert, one of the Founders of SCT who passed away this past year, on Wednesday, May 22, at 8:00 am for his extensive contributions to the field of clinical trials and the advancement of clinical trials methodology and rigor. The tribute will be followed at 8:15 by the Curtis Meinert Keynote Lecture presented by Merit Cudkowicz, MD, from Mas-

SCT President's Column

sachusetts General Hospital on "Accelerating Therapy Development in ALS and Other Neurological Disorders". Dr. Cudkowicz has pioneered advancements in neurological research in ALS from funding received from the Ice Bucket Challenge to the ongoing Healey ALS platform trial.

I am also very much looking forward to seeing the session with the David Sackett Trial of the Year awardee presented on Monday, May 20, at 9:00 am by Adam Devall, PhD, from the University of Birmingham, UK. This incredibly important trial, "Early Detection of Postpartum Hemorrhage and Treatment Using the World Health Organization MOTIVE 'First Response' Bundle: A Cluster Randomized Trial" was published in the NEJM in July of 2023 and demonstrates the far reach and importance of the work that each and every one of you do. This international cluster-randomized trial assessed a clinical intervention involving a calibrated blood-collection drape for early detection of postpartum hemorrhage and a bundle of firstresponse treatments to improve maternal outcomes of bleeding and death.

Another exciting initiative for this year was the ad-

dition of "Targeted Invited Sessions" where we asked the Board of Directors to target current and cutting edge topics in clinical trials and invite presenters to the Annual Meeting. It is my great honor to present Targeted Session 1: Breaking Through -Navigating the New Horizons of Patient-Partnered Clinical Trials Through the Expertise of Clinical Research Nursing; Targeted Session 2: Patient-Centric Clinical Trials based on Benefit-Risk: An Open DOOR; and Targeted Session 3: Catching up with PCORI – New Priorities, Innovations, and an Update on Funding Opportunities to Advance Patient-Centered Comparative Clinical Effectiveness Research.

Thank you to all of you for the work that you do in support of the Society for Clinical Trials. Please visit the SCT website at <u>https://www.sctweb.org/</u> for updates and follow up on social media. We are looking forward to a very strong attendance at the Annual Meeting and I look forward to seeing you all in person.

Dixie J. Ecklund, RN, MSN, MBA

President, Society for Clinical Trials





By Colin Begg, Editor

February, 2024 Issue Highlights

The February issue of *Clinical Trials* is primarily cacy versus a placebo when a trial uses an active devoted to a series of articles focusing on the tosis and schwannomatosis, rare conditions that lead to multiple nerve sheath tumors. This series was put together by a committee from the REiNS International Collaboration, led by Vanessa Merker. Other articles in the issue include a critique of how comparative effectiveness trials in critical care are being conducted by Verity Ford and colleagues, methodology for how to infer treatment effi-

control by Yifan Zhu and colleagues, and a stratemethodology of clinical trials in neurofibroma- gy for validating statistical programming used in clinical trials by **Carroll Gamble** and colleagues. As always we encourage you to submit your best work to the journal.

> Follow us on twitter @clintrialsj to keep up to date with the latest from the journal.

VOLUME 35,#I

45th Annual Meeting

It Takes a Village: Patient Centered Partnerships in Clinical Trials

About the Annual Meeting

The Annual Meeting of the Society for Clinical Trials is a multidisciplinary program with broad participation. The Meeting brings together the clinical trials community from academia, the pharmaceutical and device industries, government agencies, medical groups and centers and clinical research entities.

Highlights include:

- Cutting edge pre-conference workshops by leaders in the field (Pre-Conference Workshop 8: Essentials of Clinical Trials
 is only available to first-time attendees, students, and post-graduates. First-time attendees, students, and postgraduates interested in registering for this complimentary workshop must be registered for the general meeting. If you
 are a first-time attendee, have registered for the general meeting and would like to register for Pre-Conference Workshop 8: Essentials of Clinical Trials, we ask that you please email registration@sctweb.org to register for this workshop.)
- Invited sessions, targeted sessions, contributed sessions, and poster presentations
- Founders and Curtis Meinert Keynote Lectures
- Annual Thomas C. Chalmers Student Scholarship competition
- Presentation by the Sylvan Green Award winner
- Exhibitors showcasing publications, technology innovators and other resources for clinical trials
- Discussions of timely issues and research experiences among colleagues in the field
- Presentation of the SCT Class of 2024 Fellows
- Presentation of the 2023 David Sackett Trial of the Year Award
- Roundtable small group discussions on a wide range of topics
- Networking with your colleagues

This year's meeting will be Boston, MA, USA.



PAGE 4

Member Spotlight



What is your current position?

I am currently the Director of the Department of International Clinical Development at the National Cancer Center Hospital (NCCH) in Japan. I also serve as the Project Leader of the Asian Clinical Trial Network for Cancers (ATLAS) project. I am engaged in the ICH-GCP renovation as an academic representative from Japan.

What are your past positions?

For over 15 years, I served as the Director of the Operations Office of the Japan Clinical Oncology Group (JCOG), which is the largest cancer cooperative group in Japan. In that role, I engaged in the management of nationwide large-scale clinical trials across Japan. I also managed several investigator-initiated registration-directed trials, some of which contributed to obtaining drug approval in Japan.

Kenichi Nakamura, MD PhD MBA

What is your training?

I had training as a general surgeon and earned a PhD in surgical oncology at Kyoto University. I learned clinical trial methodology in the JCOG Operations Office through actual multi-center clinical trials. I also earned an MBA at the Globos University to incorporate technovate thinking into clinical trials.

What are your specific research interests or your specific interests within clinical trials?

My current interests include promoting decentralized clinical trials, building international clinical trial networks, and considering future clinical trials from regulatory and operational perspectives.

What are your hobbies (outside of work)?

I love mountain climbing and trail running. There are a lot of beautiful mountains in Japan. I also love to play with Aibo, which is an AI robot dog developed by Sony.

What role(s) did/do you play in SCT?

In 2023, I attended my first SCT annual meeting in Baltimore and found only 4 participants joined from Japan. I am one of the board members of the Japan Society of Clinical Trials and Research (JSCTR), which is a counterpart of SCT in Japan. Since I have become a member of the Outreach Committee of SCT, I would like to plan several joint initiatives between SCT and JSCTR.

What is your favorite part about being involved in clinical trials?

My favorite part is that the results of a clinical trial in which I was involved can change a patient's life for the better. Unlike a surgeon, my current position can have a positive impact on a much broader range of patients in the future.

What do you enjoy most about attending the SCT Annual Meeting?

Trial of the Year is a great session, where I can learn about the latest clinical trial trends and methodologies. Since I am not a statistician, there would be more non-statistical sessions. I would like to talk with more SCT members from now on.

What advice would you have for junior researchers just starting out in the field of clinical trials?

No path lies before me. As I press on, behind me a path appears. (Japanese proverb).

VOLUME 35,#I

IBTN 2024 Conference



If you're doing behavioural medicine, this is the place to be this May! Join us in Montreal May 16 to 18 for the IBTN 2024 Conference - Behavioural Interventions: Past, Present, and Future - a leading international conference on trials and interventions in the field of behavioural medicine.

FEATURING

- 34 experts
- From 9 countries
- And 5 continents
- Under 1 roof
- 3 keynote presentations
- 7 interactive workshops

- 12 phenomenal talks
- Over 2.5 amazing days
- 1 full plenary day
- 1 full workshop day
- 2 award ceremonies
- 1 anniversary bash

Interested in Presenting an SCT Webinar?

We encourage all SCT members interested in sharing their knowledge and expertise on a particular topic to submit a Webinar Proposal Form for the SCT Education Committee's review and consideration. To access the SCT Sponsored Webinar Proposal Form, go to <u>https://www.sctweb.org</u>, click on the Member Sign-In button and login. On the Members-Only Area Home page, click on "Propose a SCT Webinar!" in the menu on the righthand side of the screen. Complete and return the Webinar Proposal Form to <u>contact@sctweb.org</u>. We look forward to receiving your proposal!

PAGE 5

VOLUME 35,#I

THANK YOU TO OUR 2024 CORPORATE SPONSORS!

GOLD SPONSOR

FRONTIER SCIENCE FOUNDATION

Frontier Science Foundation is an accomplished nonprofit whose mission

is to collaborate with investigators and sponsors to conduct scientifically

meaningful high-quality clinical trials. Since 1975, the organization has

provided innovative, yet cost-effective, data management, biostatistics,

and technical services to a wide range of collaborators worldwide.

GOLD SPONSOR

MERCK & CO., INC.

At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than a century, we've been at the forefront of research, bringing forward medicines, vaccines and innovative health solutions for the world's most challenging diseases.

SILVER SPONSOR

BEIGENE

BeiGene is a global oncology company that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. With a broad portfolio, we are expediting development of our diverse pipeline of novel therapeutics through our internal capabilities and collaborations. We are committed to radically improving access to medicines for far more patients who need them. Our growing global team of more than 10,000 colleagues spans five continents, with administrative offices in Basel, Beijing, and Cambridge, U.S.

SILVER SPONSOR

BRISTOL MYERS SQUIBB

Bristol Myers Squibb is a leading global biopharma company focused on discovering, developing and delivering innovative medicines for patients with serious diseases in areas including oncology, hematology, immunology, cardiovascular, fibrosis and neuroscience. Our employees work every day to transform patients' lives through science.

SILVER SPONSOR

PFIZER

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety, and value in the discovery, development, and manufacture of health care products, including innovative medicines and vaccines.

SILVER SPONSOR

TEVA

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a global pharmaceutical leader with a category-defying portfolio, harnessing our generics expertise and stepping up innovation to continue the momentum behind the discovery, delivery, and expanded development of modern medicine. To learn more about how Teva is all in for better health, visit www.tevapharm.com .

SILVER SPONSOR

UNIVERSITY OF WISCONSIN

The Data Coordinating Center (DCC) is a component of the Clinical Trials Program in the Department of Biostatistics and Medical Informatics at the UW School of Medicine and Public Health. The DCC supports investigator-initiated NIH or industry-sponsored RCTs. We provide expertise in planning, conduct, monitoring, and analysis of clinical trials.

BRONZE SPONSOR

STATACORP

Stata statistical software provides everything for your data science needs—data manipulation, visualization, statistics, and automated reporting. Whether you prefer a GUI, a command line, or scripts, Stata puts the statistics you want at your fingertips. Stata is easy to use and has your back with world-class support.

BRONZE SPONSOR

AMGEN

Amgen harnesses the best of biology and technology to fight the world's toughest diseases, and make people's lives easier, fuller and longer. We helped establish the biotechnology industry, and we remain on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today.

SILVER SPONSOR

GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.com.

BRONZE SPONSOR

VERTEX

Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has approved medicines that treat the underlying causes of multiple chronic, life-shortening genetic diseases — cystic fibrosis, sickle cell disease and transfusion-dependent beta thalassemia — and continues to advance clinical and research programs in these diseases. Vertex also has a robust clinical pipeline of investigational therapies across a range of modalities in other serious diseases where it has deep insight into causal human biology, including acute and neuropathic pain, APOL1-mediated kidney disease, autosomal dominant polycystic kidney disease, type 1 diabetes, myotonic dystrophy type 1 and alpha-1 antitrypsin deficiency.

Save the Dates - Upcoming SCT Annual Meetings



45th Annual Meeting May 19-22, 2024 Boston, MA



46th Annual Meeting May 18-21, 2025 Vancouver, BC



47th Annual Meeting May 17-20, 2026 Phoenix, AZ



48th Annual Meeting May 16-19, 2027 Chicago, IL

Information About SCT

85 W. Algonquin Road Suite 550 Arlington Heights, IL 60005 (847) 427-8010

Executive Director Kevin Bragaw

Program & Governance Manager Lisa Aguado

<u>contact@sctweb.org</u>

<u>www.sctweb.org</u>





@<u>sct.org</u>



Webmaster: John Hepler Advisor to Executive Committee: Domenic Reda Newsletter Editors: I-Hsin Lin, Lee McDaniel

Executive Committee (2023-2024)

Dixie Ecklund (President) Scott R. Evans (President-Elect) Lehana Thabane (Past-President) Christopher Coffey (Treasurer) Michael Grayling (Secretary) Board of Directors (2023-2024) Kaleab Abebe (2020-2024) Jody Ciolino (2022-2026) Jonathan Cook (2023-2027) Denise Esserman (2021-2025) Elizabeth Garrett-Mayer (2023-2027) Masha Kocherginsky (2022-2026) Theodore Lystig (2022-2025) Letitia Perdue (2020-2024) Julianna Tolles (2021-2025) Committee Chairs (2023-2024) Program: Charity Patterson (Chair) Cory E. Goldstein (Co-Chair) Karla Hemming (Past Chair) Equity, Diversity & Inclusion: Kaleab Abebe (Chair) Mitra Lewis (Co-Chair) Fellows: Christopher Coffey (Chair) Anne S. Lindblad (Co-Chair) Valerie Durkalski (Past Chair)

Education:

Gustavo Jimenez-Maggiora (Chair) Sarah Gaussoin (Co-Chair) Larisa G. Tereshchenko (Past Chair) **Communication:** Andrew Althouse (Chair) I-Hsin Lin (Co-Chair) Mei-Yin Polley (Past Chair) **Development:** Pralay Mukhopadhyay (Chair) Li Wang (Co-Chair) Membership: Julie Qidwai (Chair) Cristina Murray-Krezan (Co-Chair) Dikla Blumberg (Past Chair) Nominating: Sameer Parpia (Chair) Sharon Love (Co-Chair) Outreach: Amarjot Kaur (Chair) Susan Halabi (Co-Chair) Rick Chappell (Past Chair) **Student Scholarship:** Ludovic Tringuart (Chair) Farah Khandwala (Co-Chair) Michael Grayling (Past Chair) Trial of the Year: Andrew Cook (Chair) Jessica Overbey (Co-Chair) Suzanne Dahlberg (Past Chair)